Topical gabapentin and its relation to cutaneous innervation in symptomatic lymphocytic primary cicatricial alopecia
Sara Bohjanen, Brian D. McAdams, Nasia Mead, Adam Loavenbruck, George L. Wilcox, Briana Paiewonsky, Javed Shaik, Maria K. Hordinsky
TL;DR
This pilot study tested topical gabapentin for symptom relief in a skin condition called lymphocytic primary cicatricial alopecia.
Contribution
The study explores the novel use of topical gabapentin for managing symptoms in a specific type of hair loss condition.
Findings
Topical gabapentin significantly reduced symptoms in participants.
No significant changes in nerve fibre density or neuropeptide expression were observed.
Abstract
In this pilot study, participants with symptomatic lymphocytic primary cicatricial alopecia applied 6% topical gabapentin solution twice daily to affected areas for 12 weeks. There was a significant reduction in symptoms, but no pronounced effect on nerve fibre density or neuropeptide expression.
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHair Growth and Disorders · Botulinum Toxin and Related Neurological Disorders · Cancer Treatment and Pharmacology